We are live on ! Find out more

53 hedge funds and large institutions have $63.9M invested in Exagen in 2025 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 16 increasing their positions, 6 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

229% more call options, than puts

Call options by funds: $56K | Put options by funds: $17K

214% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 7

185% more capital invested

Capital invested by funds: $22.4M → $63.9M (+$41.5M)

167% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 6

39% more funds holding

Funds holding: 38 → 53 (+15)

7.07% more ownership

Funds ownership: 34.84% → 41.91% (+7.1%)

Holders
53
Holders Change
+15
Holders Change %
+39.47%
% of All Funds
0.7%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
22
Increased
16
Reduced
6
Closed
7
Calls
$56K
Puts
$17K
Net Calls
+$39K
Net Calls Change
+$87K

XGN Hedge Fund Activity: Q2 2025 in Review

53 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Exagen (XGN) for Q2 2025, worth a combined $63.9M — up 185% from $22.4M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new XGN positions and 7 closed out — a net gain of 15 holders — while 16 added to existing stakes and 6 trimmed.

The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $4.37M. The largest seller was Perkins Capital Management, cutting an estimated $1.16M.

  • 53 institutional investors held Exagen (XGN) as of Q2 2025, up from 38 in Q1 2025.
  • Funds reported $63.9M of Exagen stock for Q2 2025, up 185% quarter-over-quarter.
  • 22 funds opened new Exagen positions in Q2 2025 and 7 closed out, a net change of +15 holders.
  • The largest Exagen buyer in Q2 2025 was Balyasny Asset Management, an estimated $4.37M added.
  • The largest Exagen seller in Q2 2025 was Perkins Capital Management, an estimated $1.16M sold.

Based on aggregated 13F filings for Q2 2025.